Pathological and Physiological Factors Affecting Drug Absorption, Distribution, Elimination, and Response in Man

  • L. F. Prescott
Chapter
Part of the Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology book series (HEP, volume 28 / 3)

Abstract

Although drugs are used primarily for the treatment of disease, surprisingly little is known of the way in which disease states or physiological factors modify drug action in man. In contrast, extensive studies in laboratory animals have shown that these factors can have striking effects which if applied to man would have enormous clinical significance. The failure to apply this basic knowledge to clinical medicine amounts virtually to negligence on the part of the medical profession.

Keywords

Drug Absorption Gastric Emptying Chronic Liver Disease Drug Metabolism Plasma Protein Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adjepon-Yamoah, K.K., Scott, D.B., Prescott, L.F.: Impaired absorption and metabolism of oral lidocaine in patients undergoing laparoseopy. Brit. J. Anesth. 45, 143–147 (1973).CrossRefGoogle Scholar
  2. Andersson, S.: Variation in gastrointestinal functions influencing the absorption of drugs. Acta Pharmacol. (Kbh.) 29, Suppl. 3, 103–108 (1971).CrossRefGoogle Scholar
  3. Anton, A.H., Corey, W.T.: Interindividual differences in the protein binding of sulfonamides: the effect of disease and drugs. Acta pharmacol. (Kbh.) 29, Suppl. 3, 134–151 (1971).CrossRefGoogle Scholar
  4. Armstrong, B.K., Ukich, A.W., Goatcher, P.M.: Plasma salicylate levels in rheumatoid arthritis produced by four different salicylate preparations. Med. J. Aust. 2, 181–182 (1970).PubMedGoogle Scholar
  5. Balasubramaniam, K., Mawer, G.E., Pohl, J.E.F., Simons, P. J.G.: Impairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency. Brit. J. Pharmacol. 45, 360–367 (1972).Google Scholar
  6. Balasubramaniam, K., Mawer, G.E., Simons, P. J.: The influence of dose on the distribution and elimination of amylobarbitone in healthy subjects. Brit. J. Pharmacol. 40, 578–579 P. (1970).Google Scholar
  7. Ballinger, B., Browning, M., O’Malley, K., Stevenson, I.H.: Drug-metabolizing capacity in states of drug dependence and withdrawal. Brit. J. Pharmacol. 45, 638–643 (1972).Google Scholar
  8. Baraka, A., Gabali, F.: Correlation between tubocurarine requirements and plasma protein pattern. Brit. J. Anaesth. 40, 89–93 (1968).PubMedCrossRefGoogle Scholar
  9. Beermann, B., Hellström, K., Rosen, A.: On the metabolism of propantheline in man. Clin. Pharmacol. Ther. 13, 212–220 (1972).PubMedGoogle Scholar
  10. Bellet, S., Roman, L.R., Boza, A.: Relation between serum quinidine levels and renal function. Amer. J. Cardiol. 27, 368–371 (1971).PubMedCrossRefGoogle Scholar
  11. Beresford, C.H., Neale, R.J., Brooks, O.G.: Iron absorption and pyrexia. Lancet 1971 I, 568–572.CrossRefGoogle Scholar
  12. Bianchine, J.R., Callmlim, L.R., Morgan, J.P., Dujuvne, C.A., Lasagna, L.: Metabolism and absorption of L-3, 4-dihydroxyphenylalanine in patients with Parkinson’s disease. Ann. N. Y. Acad. Sci. 179, 126–140 (1971).PubMedCrossRefGoogle Scholar
  13. Bigland, B., Goetzee, B., MacLagan, J., Zaimis, E.: The effect of lowered muscle temperature on the action of neuromuscular blocking agents. J. Physiol. (Lond.) 141, 425–434 (1958).Google Scholar
  14. Bluemle, L.W., Goldberg, M. J.: Renal accumulation of salicylate and phenacetin; possible mechanisms in the nephrotoxicity of analgesic abuse. J. clin. Invest. 47, 2507–2514 (1968).CrossRefGoogle Scholar
  15. Bogoch, A., Davis, T.W., Jow, E., Wrenshall, G.A.: The clinical response and amount of insulin extractable from the pancreas in diabetic patients treated with oral hypoglycemic drugs. Canad. med. Ass. J. 81, 347–356 (1959).PubMedGoogle Scholar
  16. Brodie, B.B.: Physicochemical factors in drug absorption. In: Binns, T.B. (Ed.): Absorption and distribution of drugs, pp. 16–48. Baltimore: Williams and Wilkins 1964.Google Scholar
  17. Chignell, C.F., Vesell, E.S., Starkweather, D.K., Berlin, C.M.: The binding of sulfa-phenazole to fetal, neonatal, and adult human plasma albumin. Clin. Pharmacol. Ther. 12, 897–901 (1971).PubMedGoogle Scholar
  18. Clarke, R.A., Julian, D.G., Nimmo, J., Prescott, L.F., Talbot, R.: Clinical pharmacological studies of Kö 1173—a new antiarrhythmic agent. Brit. J. Pharmacol. Abstr. 47, 622–623 P. (1973).Google Scholar
  19. Conney, A.H., Welch, R., Kuntzman, R., Chang, R., Jacobson, M., Munrofaure, A.D., Peck, A.W., Bye, A., Poland, A., Poppers, P.J., Finster, M., Wolff, J.A.: Effects of environmental chemicals on the metabolism of drugs, carcinogens, and normal body constituents in man. Ann. N. Y. Acad. Sci. 179, 155–172 (1971).PubMedCrossRefGoogle Scholar
  20. Covino, B.G.: Local anesthesia. New Engl. J. Med. 286, 1035–1042 (1972).PubMedCrossRefGoogle Scholar
  21. Creaven, P.J., Allen, L.M.: Renal clearance of camptothecin sodium in man; effect of urine volume. Fifth International Congress on Pharmacology, San Francisco, Abstr. No. 283, p. 48 (1972).Google Scholar
  22. Crounse, R.G.: Human pharmacology of griseofulvin: The effect of fat intake on gastrointestinal absorption. J. invest. Derm. 37, 529–533 (1961).PubMedCrossRefGoogle Scholar
  23. Curtis, J.R., Marshall, M.J.: Cephaloridine serum levels in patients on maintenance hemodialysis. Brit. med. J. 1970 II, 149–151.CrossRefGoogle Scholar
  24. Cutler, R.E., Orme, B.M.: Correlation of serum creatinine concentration and kanamycin half-life: Therapeutic implications. J. Amer. med. Ass. 209, 539–542 (1969).CrossRefGoogle Scholar
  25. Das, K.M., Eastwood, M.A.: Personal communication.Google Scholar
  26. Davis, A. E., Pirola, R.C.: Absorption of phenoxymethyl penicillin in patients with steatorrhea. Aust. Ann. Med. 17, 63–65 (1968).PubMedGoogle Scholar
  27. Dettli, L., Spring, P., Habersang, R.: Drug dosage in patients with impaired renal function. Postgrad, med. J. 46, Suppl., 32–35 (1970).CrossRefGoogle Scholar
  28. DoLuisio, J.T., Tan, G.H., Billups, N.F., Diamond, L.: Drug absorption. II. Effect of fasting on intestinal drug absorption. J. pharm. Sci. 58, 1200–1202 (1969).PubMedCrossRefGoogle Scholar
  29. Dreifus, L.S., Duarte, C., Kodama, R., Moyer, J.H.: The effect of thiazide diuretics on the abnormal kidney. Ann. intern. Med. 53, 1170–1179 (1960).PubMedGoogle Scholar
  30. Dundee, J. W.: Thiopentone and other thiobarbiturates, p. 137. Edinburgh: Livingstone 1956.Google Scholar
  31. Dundee, J. W., Richards, R.K.: The effect of azotemia upon the action of intravenous barbiturate anesthesia. Anesthesiology 15, 333–346 (1954).PubMedCrossRefGoogle Scholar
  32. Ebadi, M.S., Kugel, R.B.: Alteration in metabolism of acetylsalicylic acid in children with Down’s syndrome: Decreased plasma binding and formation of salicyluric acid. Pediat. Res. 4, 187–193 (1970).PubMedCrossRefGoogle Scholar
  33. Fischer, E.: Renal excretion of sulfadimidine in normal and uraemic subjects. Lancet 1972II, 210–212.CrossRefGoogle Scholar
  34. Gilbertson, A.A., Boulton, T.B.: Anesthesia in difficult situations. The influence of disease on pre-operative preparation and choice of anesthetic. Anesthesia 22, 607–630 (1967).CrossRefGoogle Scholar
  35. Gillette, J.R.: Factors affecting drug metabolism. Ann. N.Y. Acad. Sci. 179, 43–66 (1971).PubMedCrossRefGoogle Scholar
  36. Gladtke, E.: Beeinflussung der Arzneimitteltherapie durch pathologische Zustände. J. mond. Pharm. (La Haye) 14, 230–250 (1971).Google Scholar
  37. Gower, P.E., Dash, C.H.: Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic. Brit. J. Pharmacol. 37, 738–747 (1969).Google Scholar
  38. Gwilt, J.R., Robertson, A., Goldman, L., Blanchard, A.W.: The absorption characteristics of paracetamol tablets in man. J. Pharm. Pharmacol. 15, 445–453 (1963).PubMedCrossRefGoogle Scholar
  39. Haass, A., Lullmann, H., Peters, T.: Absorption rates of some cardiac glycosides and portal blood flow. Europ. J. Pharmacol. 19, 366–370 (1972).CrossRefGoogle Scholar
  40. Hammar, C.-H., Prellwitz, W.: Die Glucuronidbildung nach peroraler Belastung mit Acet-anilid bei chronischer Hepatitis und Lebercirrhose. Klin. Wschr. 44, 1010–1014 (1966).PubMedCrossRefGoogle Scholar
  41. Harrison, T.S.: Adrenal medullary and thyroid relationships. Physiol. Rev. 44, 161–185 (1964).PubMedGoogle Scholar
  42. Hartiala, K., Kasanen, A., Raussi, M.: The absorption of salicylamide in pernicious anemia, gastric achylia, and peptic ulcer. Ann. Med. exp. Fenn. 41, 549–553 (1963).PubMedGoogle Scholar
  43. Hayes, A.H.: Intravenous infusion of lidocaine in the control of ventricular arrhythmias. In: Scott, D.B., Julian, D.G. (Eds.): Lidocaine in the treatment of ventricular arrhythmias, pp. 189–199. Edinburgh: Livingstone 1971.Google Scholar
  44. Heading, R.C., Nlmmo, J., Prescott, L.F., Tothill, P.: The dependence of paracetamol absorption on the rate of gastric emptying. Brit. J. Pharmacol. 47, 415–421 (1973).Google Scholar
  45. Heizer, W.D., Smith, T. W., Goldfinger, S.E.: Absorption of digoxin in patients with malabsorption syndromes. New Engl. J. Med. 285, 257–259 (1971).PubMedCrossRefGoogle Scholar
  46. Held, H., Oldershausen, H.F.: Zur Pharmakokinetik von Meprobamat bei chronischen Hepatopathien und Arzneimittelsucht. Klin. Wschr. 47, 78–80 (1969).PubMedCrossRefGoogle Scholar
  47. Held, H., Oldershausen, H.F.: Drug metabolism in acute and chronic liver disease. Digestion 4, 151 (Abstr.) (1971).Google Scholar
  48. Howell, A., Sutherland, R., Robinson, G.N.: Effect of protein binding on levels of ampi-cillin and cloxacillin in synovial fluid. Clin. Pharmacol. Ther. 13, 724–732 (1972).PubMedGoogle Scholar
  49. Jafpe, J.M., Colaizzi, J.L., Barry, H.: Effects of dietary components on GI absorption of acetaminophen tablets in man. J. pharm. Sci. 60, 1646–1650 (1971).CrossRefGoogle Scholar
  50. Jollow, D.J., Mitchell, J.R., Potter, W.Z., Davis, D.C., Gillette, J.R., Brodie, B.B.: Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. exp. Ther. 187, 195–202 (1973).PubMedGoogle Scholar
  51. Kater, R.M.H., Roggin, G., Tobon, F., Zieve, P., Iber, F.L.: Increased rate of clearance of drugs from the circulation of alcoholics. Amer. J. med. Sci. 258, 35–39 (1969).PubMedCrossRefGoogle Scholar
  52. Kekki, M., Pyörälä, K., Mustala, O., Salmi, H., Jussila, J., Siurala, M.: Multicompartment analysis of the absorption kinetics of warfarin from the stomach and small intestine. Int. J. clin. Pharmacol. 5, 209–211 (1971).Google Scholar
  53. King, J. O., Denborough, M.A., Zapf, P. W.: Inheritance of malignant hyperpyrexia. Lancet 1972I, 365–370.CrossRefGoogle Scholar
  54. Koch-Weser, J.: Pharmacokinetics of procainamide in man. Ann. N.Y. Acad. Sci. 179, 370–382 (1971).PubMedCrossRefGoogle Scholar
  55. Koch-Weser, J., Klein, S.W.: Procainamide dosage schedules, plasma concentrations and clinical effects. J. Amer. med. Ass. 215, 1454–1460 (1971).CrossRefGoogle Scholar
  56. Kojima, S., Smith, R.B., Doluisio, J.T.: Drug absorption. V. Influence of food on oral absorption of phenobarbital in rats. J. pharm. Sci. 60, 1639–1641 (1971).PubMedCrossRefGoogle Scholar
  57. Kuntzman, R.G., Tsai, I., Brand, L., Mark, L.C.: The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. Clin. Pharmacol. Ther. 12, 62–67 (1971).PubMedGoogle Scholar
  58. Kutt, H., Winters, W., Scherman, R., McDowell, F.: Diphenylhydantoin and phenobarbital toxicity. Arch. Neurol. (Chic.) 11, 649–656 (1964).PubMedCrossRefGoogle Scholar
  59. Laidlaw, J., Read, A. E., Sherlock, S.: Morphine tolerance in hepatic cirrhosis. Gastroenterology 40, 389–396 (1961).PubMedGoogle Scholar
  60. Letteri, J.M., Mellk, H., Louis, S., Kutt, H., Durante, P., Glazko, A.: Diphenylhydantoin metabolism in uremia. New. Engl. J. Med. 285, 648–652 (1971).PubMedCrossRefGoogle Scholar
  61. Levi, A. J., Sherlock, S., Walker, D.: Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968I, 1275–1279.CrossRefGoogle Scholar
  62. Levine, R.R.: Factors affecting gastrointestinal absorption of drugs. Digest. Dis. 15, 171–188 (1970).CrossRefGoogle Scholar
  63. Levy, G., Gibaldi, M., Procknal, J.A.: Effect of an anticholinergic agent on riboflavin absorption in man. J. pharm. Sci. 61, 798–799 (1972).PubMedCrossRefGoogle Scholar
  64. Lewis, G. P., Jusko, W.J., Burke, C.W., Graves, L.: Prednisone side-effects and serum-protein levels. Lancet 1971II, 778–780.CrossRefGoogle Scholar
  65. Luchi, R.J., Gruber, J.W.: Unusually large digitalis requirements: a study of altered digoxin metabolism. Amer. J. Med. 45, 322–328 (1968).PubMedCrossRefGoogle Scholar
  66. Lund, L., Berlin, A., Lunde, P.K.M.: Plasma protein binding of diphenylhydantoin in patients with epilepsy. Clin. Pharmacol. Ther. 13, 196–200 (1972).PubMedGoogle Scholar
  67. MacDonald, H., Place, V.A., Falk, H., Darken, M.A.: Effect of food on absorption of sulfonamides in man. Chemotherapia (Basel) 12, 282–285 (1967).CrossRefGoogle Scholar
  68. Mason, D.T., Braunwald, E.: Symposium on congestive heart failure. II. Digitalis: new facts about an old drug. Amer. J. Cardiol. 22, 151–161 (1968).PubMedCrossRefGoogle Scholar
  69. Mattila, M.J., Friman, A., Larmi, T.K.L, Koskinen, R.: Absorption of ethionamid, iso-niazid, and aminosalicylic acid from the post-resection gastrointestinal tract. Ann. Med. exp. Fenn. 47, 209–212 (1969).PubMedGoogle Scholar
  70. Mawer, G.E., Miller, N.E., Turnberg, L.A.: Metabolism of amylobarbitone in patients with chronic liver disease. Brit. J. Pharmacol. 44, 549–560 (1972).Google Scholar
  71. Mcgilveray, I.J., Mattok, G.L.: Some factors affecting the absorption of paracetamol. J. Pharm. Pharmacol. 24, 615–619 (1972).PubMedCrossRefGoogle Scholar
  72. McHenry, M.C., Gavan, T.L., Gifford, R.W., Jr., Geurkink, N.A., van Ommen, R.A., Town, M.A., Wagner, J.G.: Gentamicin dosages for renal insufficiency: Adjustments based on endogenous creatinine clearance and serum creatinine concentration. Ann. intern. Med. 74, 192–197 (1971).PubMedGoogle Scholar
  73. Menguy, R., Desbaillets, L., Okabe, S., Masters, Y.F.: Abnormal aspirin metabolism in patients with cirrhosis and its possible relationship to bleeding in cirrhotics. Ann. Surg. 176, 412–418 (1972).PubMedCrossRefGoogle Scholar
  74. Meyer, M.B., Zelechowski, K.: Intramuscular lidocaine in normal subjects. In: Scott, D.B., Julian, D.G. (Eds.): Lidocaine in the treatment of ventricular arrhythmias, pp. 161–168. Edinburgh: Livingstone 1971.Google Scholar
  75. Mitchell, J.R., Jollow, D.J., Potter, W.Z., Davis, D.C., Gillette, J.R., Brodie, B.B.: Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol, exp. Ther. 187, 185–194 (1973).Google Scholar
  76. Murray-Lyon, I.M., Young, J., Parkes, J. D., Kntll-Jones, R.P., Williams, R.: Clinical and electroencephalographs assessment of diazepam in liver disease. Brit. med. J. 4, 265–266 (1971).PubMedCrossRefGoogle Scholar
  77. Myhre, E., Brodwall, E.K., Stenbaek, O., Hansen, T.: Plasma turnover of methyldopa in advanced renal failure. Acta med. scand. 191, 343–347 (1972).PubMedGoogle Scholar
  78. Nanra, R.S., Hicks, J.D., McNamara, J.H., Lie, J.T., Leslie, D.W., Jackson, B., Kincaid-Smith, P.: Seasonal variation in the post-mortem incidence of renal papillary necrosis. Med. J. Aust. 1, 293–296 (1970).Google Scholar
  79. Nelson, E.: Rate of metabolism of tolbutamide in test subjects with liver disease or with impaired renal function. Amer. J. med. Sci. 248, 657–659 (1964).PubMedCrossRefGoogle Scholar
  80. Nelson, J. D., Shelton, S., Kusmiesz, H.T., Haltalin, K.C.: Absorption of ampicillin and nalidixic acid by infants and children with acute shigellosis. Clin. Pharmacol. Ther. 13, 879–886 (1972).PubMedGoogle Scholar
  81. Nimmo, J., Heading, R.C., Tothill, P., Prescott, L.F.: Pharmacological modification of gastric emptying: effects of propantheline and metoclopramide on paracetamol absorption. Brit. med. J. 1, 587–589 (1973).PubMedCrossRefGoogle Scholar
  82. Odar-Cederlöf, L., Lunde, P., Sjöqvist, F.: Abnormal pharmacokinetics of phenytoin in a patient with uremia. Lancet 1970II, 831–832.CrossRefGoogle Scholar
  83. Ohnhaus, E.E.: The pharmacokinetics of unchanged pindolol in patients with impaired renal function. Brit. J. Pharmacol. Abstr. 47, 620–621 P. (1973).Google Scholar
  84. O’Malley, K., Crooks, J., Duke, E., Stevenson, I.H.: Effect of age and sex on human drug metabolism. Brit. med. J. 1971 III, 607–609.CrossRefGoogle Scholar
  85. Peterson, O.L., Finland, M.: The effect of food and alkali on the absorption and excretion of sulfonamide drugs after oral and duodenal administration. Amer. J. med. Sci. 204, 581–588 (1942).Google Scholar
  86. Place, V.A., Benson, H.: Dietary influences on therapy with drugs. J. mond. Pharm. 14, 261–278 (1971).Google Scholar
  87. Potter, W.Z., Davis, D.C., Mitchell, J. R., Jollow, D.J., Gillette, J. R., Brodle, B.B.: Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. J. Pharmacol. exp. Ther. 187, 203–210 (1973).PubMedGoogle Scholar
  88. Prescott, L.F.: Mechanisms of renal excretion of drugs (with special reference to drugs used by anesthetists). Brit. J. Anesth. 44, 246–251 (1972).CrossRefGoogle Scholar
  89. Prescott, L.F., Nimmo, J.: Generic inequivalence—clinical observations. Acta pharmacol. (Kbh.) 29, Suppl. 3, 288–303 (1971a).CrossRefGoogle Scholar
  90. Prescott, L.F., Nimmo, J.: Drug therapy—physiological considerations. J. mond. Pharm. (La Haye) 14, 253–260 (1971b).Google Scholar
  91. Prescott, L.F., Nimmo, J.: Plasma lidocaine concentrations during and after prolonged infusions in patients with myocardial infarction. In: Scott, D.B., Julian, D.G. (Eds.): Lidocaine in the treatment of ventricular arrhythmias, pp. 168–177. Edinburgh: Livingstone 1971c.Google Scholar
  92. Prescott, L. F., Roscoe, P., Forrest, J. A. H.: Plasma concentrations and drug toxicity. II. Toxicity in man. In: Davies, D.S., Pritchard, B. N. C. (Eds): Biological effects of drugs in relation to their plasma concentrations, pp. 51–81. London: Macmillan 1973.Google Scholar
  93. Prescott, L. F., Roscoe, P., Wright, N., Brown, S.S.: Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971I, 519–522.CrossRefGoogle Scholar
  94. Prescott, L.F., Steel, R.F., Ferrier, W.R.: The effects of particle size on the absorption of phenacetin in man. Clin. Pharmacol. Ther. 11, 496–504 (1970).PubMedGoogle Scholar
  95. Prescott, L.F., Stevenson, I.H.: Liver disease and drug metabolism in man. In: Proceedings of the Fifth International Congress on Pharmacology. Basel: Karger 3, 182–190, 1973.Google Scholar
  96. Price-Evans, D.A.: Inter-individual differences in the metabolism of drugs: the role of genetic factors. Acta pharmacol. (KM.) 29, Suppl. 3, 156–163 (1971).CrossRefGoogle Scholar
  97. Reidenberg, M.M.: Renal function and drug action, pp. 1–3, 33–37. Philadelphia: Saunders 1971.Google Scholar
  98. Reidenberg, M.M.: Effect of kidney disease on pharmacokinetics and drug response. In: Proceedings of the Fifth International Congress on Pharmacology. Basel: Karger 1973.Google Scholar
  99. Reidenberg, M.M., James, M., Dring, L.G.: The rate of procaine hydrolysis in serum of normal subjects and diseased patients. Clin. Pharmacol. Ther. 13, 279–284 (1972).PubMedGoogle Scholar
  100. Reidenberg, M.M., Odar-Cederlöf, I., von Bahr, C., Borga, O., Sjöqvest, F.: Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. New Engl. J. Med. 285, 264–267 (1971).PubMedCrossRefGoogle Scholar
  101. Ristola, P., Pyörälä, K.: Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta med. scand. 192, 183–188 (1972).PubMedCrossRefGoogle Scholar
  102. Ryan, J.F., Kagen, L.J., Hyman, A.I.: Myoglobinemia after a single dose of succinyl-choline. New Engl. J. Med. 285, 824–827 (1971).PubMedCrossRefGoogle Scholar
  103. Sales, J.E.L., Sutclipfe, M., O’Grady, F.: Cephalexin levels in human bile in presence of biliary tract disease. Brit. med. J.1972 III, 441–443.CrossRefGoogle Scholar
  104. Schedl, H.P., Clifton, J.A.: Cortisol absorption in man. Gastroenterology 44, 134–145 (1963).PubMedGoogle Scholar
  105. Scheiner, J., Altemeier, W.A.: Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg. Gyn. Obstet. 114, 9–14 (1962).Google Scholar
  106. Schoene, B., Fleischmann, R. A., Remmer, H.: Determination of drug metabolizing enzymes in needle biopsies of human liver. Europ. J. clin. Pharmacol. 4, 65–73 (1972).CrossRefGoogle Scholar
  107. Schreiner, G.E.: Dialysis of poisons and drugs—Annual review. Trans. Amer. Soc. Artif. Int. Organs 16, 544–568 (1970).Google Scholar
  108. Schröder, H., Campbell, D.E.S.: Absorption, metabolism, and excretion of salicylazosulfa-pyridine in man. Clin. Pharmacol. Ther. 13, 539–551 (1972).PubMedGoogle Scholar
  109. Sereni, F., Perletti, L., Marubini, E., Mars, G.: Pharmacokinetic studies with a long-acting sulfonamide in subjects of different ages. Pediat. Res. 2, 29–37 (1968).PubMedCrossRefGoogle Scholar
  110. Sessions, J.T., Minkel, H.P., Bullard, J.C., Ingelfinger, F.J.: The effect of barbiturates in patients with liver disease. J. clin. Invest. 33, 1116–1127 (1954).PubMedCrossRefGoogle Scholar
  111. Shideman, F.E., Kelly, A.R., Lee, L.E., Lowell, V.F., Adams, B.J.: The role of the liver in the detoxification of thiopental (pentothal) by man. Anesthesiology 10, 421–427 (1949).PubMedCrossRefGoogle Scholar
  112. Siegers, C.-P., Strubelt, O., Back, G.: Inhibition by caffeine of ethanol absorption in rats. Europ. J. Pharmacol. 20, 181–187 (1972).CrossRefGoogle Scholar
  113. Siurala, M., Mttstala, O., Jtjssila, J.: Absorption of acetylsalicylic acid by a normal and atrophic gastric mucosa. Scand. J. Gastroent. 4, 269–273 (1969).PubMedGoogle Scholar
  114. Sotaniemi, E., Huhti, E., Arvela, P., Koivisto, O.: Tolbutamide clearance from the blood in hypercapnia. Scand. J. clin. Lab. Invest. 27, Suppl. 78 (Abstr.) (1971).Google Scholar
  115. Smith, R.B., Petruscak, J.: Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth. Anaig. Curr. Res. 51, 202–205 (1972).Google Scholar
  116. Stenbaek, Ø., Myhre, E., Brodwall, E.K., Hansen, T.: Hypotensive effect of methyldopa in renal failure associated with hypertension. Acta med. scand. 191, 333–337 (1972).PubMedGoogle Scholar
  117. Thompson, F.D., Joekes, A.M., Foulkes, D.M.: Pharmacodynamics of propranolol in renal failure. Brit. med. J. 1972II, 434–436.CrossRefGoogle Scholar
  118. Thomson, P.D., Rowland, M., Melmon, K.L.: The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. Amer. Heart J. 82, 417–421 (1971).PubMedCrossRefGoogle Scholar
  119. Tobey, R.E., Jacobsen, P.M., Kahle, C.T., Clubb, R.J., Dean, M.A.: The serum potassium response to muscle relaxants in neural injury. Anesthesiology 37, 332–337 (1972).PubMedCrossRefGoogle Scholar
  120. Tolomie, J.D., Joyce, T.H., Mitchell, G.D.: Succinylcholine danger in the burned patient. Anesthesiology 28, 467–470 (1967).CrossRefGoogle Scholar
  121. Ueda, H., Sakurai, T., Ota, M., Nakajima, A., Kamii, K., Maezawa, H.: Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease, Diabetes 12, 414–419 (1963).PubMedGoogle Scholar
  122. Vagenakis, A.G., Cote, R., Miller, M.E., Braverman, L.E., Stohlman, F., Jr.: Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis. Johns Hopk. med. J. 131, 69–75 (1972).Google Scholar
  123. Venho, V.M.K., Jussila, J., Aukee, S.: Drug absorption in man after gastric suergry. Fifth International Congress on Pharmacology, San Francisco. Abstract No. 1445, 241 (1972).Google Scholar
  124. Waddell, W.J., Butler, T.C.: The distribution and excretion of phénobarbital. J. clin. Invest. 36, 1217–1226 (1957).PubMedCrossRefGoogle Scholar
  125. Webb, D.I., Chodos, R.B., Mahar, C.Q., Faloon, W.W.: Mechanism of vitamin B12 malabsorption in patients receiving colchicine. New Engl. J. Med. 279, 845–850 (1968).PubMedCrossRefGoogle Scholar
  126. Wechselberg, K.: Salizylsäure-Vergiftung durch perkutane Resorption l%iger Salizyl-vaseline. Pädiat. Prax. 7, 431–433 (1968).Google Scholar
  127. Whelton, A., Sapir, D.G., Carter, G.G., Kramer, J., Walker, W.G.: Intrarenal distribution of penicillin, cephalothin, ampicillin, and Oxytetracycline during varied states of hydration. J. Pharmacol, exp. Ther. 179, 419–428 (1971).Google Scholar
  128. White, R.J., Chamberlain, D.A., Howard, M., Smith, T.W.: Plasma concentrations of digoxin after oral administration in the fasting and postprandial state. Brit. med. J. 1971I, 380–381.CrossRefGoogle Scholar
  129. Wright, N., Prescott, L.F.: Paracetamol overdosage: potentiation of hepatotoxicity by previous drug therapy. Scot. med. J. 18, 56–58 (1973).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1975

Authors and Affiliations

  • L. F. Prescott

There are no affiliations available

Personalised recommendations